Synthetic peptides as cancer vaccines
Identifieur interne : 003379 ( Main/Exploration ); précédent : 003378; suivant : 003380Synthetic peptides as cancer vaccines
Auteurs : Roshni Sundaram [États-Unis] ; Naveen K. Dakappagari [États-Unis] ; Pravin T. P. Kaumaya [États-Unis]Source :
- Peptide Science [ 0006-3525 ] ; 2002.
English descriptors
- Teeft :
- Acad, Active immunotherapy, Adenocarcinoma, Adjuvant, Allele, Amino acids, Animal models, Antibody, Antibody response, Antibody responses, Antigen, Antigen presentation, Antigen processing, Antitumor, Antitumor immunity, Biodegradable microspheres, Biol chem, Cancer immunol immunother, Cancer patients, Cancer vaccines, Cancerous cells, Cell epitopes, Cell surface, Cellular response, Cellular transformation, Chain length, Clin, Clin cancer, Clin oncol, Clinical trials, Conformational epitopes, Costimulatory, Costimulatory molecules, Ctls, Curr opin immunol, Cytokine, Cytotoxic, Cytotoxic responses, Dakappagari, Dendritic cells, Different types, Disis, Early stage cancer, Envelope glycoprotein, Epitope, Epitope peptides, Existent immunity, Foreign species, Further studies, Gmcsf, Granulocyte monocyte colony, Helper epitopes, High frequency, High titered antibodies, Humoral, Immune, Immune response, Immune responses, Immune system, Immunization, Immunogenic, Immunol, Immunotherapeutic strategies, Immunotherapy, Kaumaya, Komen breast cancer foundation, Lesser extent, Major histocompatibility, Mammary tumors, Melanoma, Melanoma antigen, Melanoma antigens, National cancer institute, National institutes, Native protein, Natl, Nitric oxide, Objective tumor regressions, Ohio state university, Oncogenic virus, Ovarian cancer patients, Peptide, Peptide epitope, Peptide vaccine, Peptide vaccines, Peripheral blood, Precise mechanism, Primary sequence, Prime ctls, Proc, Proc natl acad, Professional antigen, Promiscuous, Promiscuous epitopes, Radiation therapy, Rational design, Recent years, Receptor, Schematic representation, Second signal, Semin immunol, Side effects, Subsequent tumor challenge, Such study, Sundaram, Synthetic peptide vaccines, Synthetic peptides, Transgenic, Transgenic mice, Transgenic mouse model, Tumor, Tumor antigen, Tumor antigens, Tumor cells, Tumor development, Tumor growth, Tumor immunity, Tumor site, Tumor vaccines, Vaccination, Vaccination strategies, Vaccine, Vaccine strategies, Viral, Wiley periodicals.
Abstract
Effective cancer therapy or prevention has been the dream of physicians and scientists for many years. Although we are still very far from our ultimate goal of cancer prevention, significant milestones have been realized in terms of our knowledge base and understanding of the pathogenesis of cancerous cells and the involvement of the immune system against both self‐ and virus‐associated tumor antigens. Immunotherapeutic strategies are now accepted to being superior in terms of the exquisite specificity that they offer in targeting only tumor cells as opposed to the existent chemotherapy or radiation therapy that is more general and invasive with many associated side effects. There are several immunotherapeutic strategies that are currently under investigation. This review primarily focuses on the significant advances made in the use of synthetic peptides in the development of subunit cancer vaccines. We have attempted to highlight some of the fundamental issues regarding antigen processing and presentation, Major Histocompatibility Complex (MHC) restriction, T‐cell help, structural determinants in antibody recognition, and the use of these concepts in the rational design and delivery of peptide vaccines to elicit protective humoral and cell mediated immune responses. The recent use of costimulatory molecules and cytokines to augment immune responses also has been discussed along with the contributions of our laboratory to the field of synthetic peptide vaccine development. © 2002 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 66: 200–216, 2002
Url:
DOI: 10.1002/bip.10258
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002449
- to stream Istex, to step Curation: 002449
- to stream Istex, to step Checkpoint: 000D38
- to stream Main, to step Merge: 003415
- to stream Main, to step Curation: 003379
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synthetic peptides as cancer vaccines</title><author><name sortKey="Sundaram, Roshni" sort="Sundaram, Roshni" uniqKey="Sundaram R" first="Roshni" last="Sundaram">Roshni Sundaram</name></author><author><name sortKey="Dakappagari, Naveen K" sort="Dakappagari, Naveen K" uniqKey="Dakappagari N" first="Naveen K." last="Dakappagari">Naveen K. Dakappagari</name></author><author><name sortKey="Kaumaya, Pravin T P" sort="Kaumaya, Pravin T P" uniqKey="Kaumaya P" first="Pravin T. P." last="Kaumaya">Pravin T. P. Kaumaya</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1461C1780AD6A3BD609EEA614C751214DB5382AF</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/bip.10258</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-KQS9B0KM-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002449</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002449</idno><idno type="wicri:Area/Istex/Curation">002449</idno><idno type="wicri:Area/Istex/Checkpoint">000D38</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D38</idno><idno type="wicri:doubleKey">0006-3525:2002:Sundaram R:synthetic:peptides:as</idno><idno type="wicri:Area/Main/Merge">003415</idno><idno type="wicri:Area/Main/Curation">003379</idno><idno type="wicri:Area/Main/Exploration">003379</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Synthetic peptides as cancer vaccines</title><author><name sortKey="Sundaram, Roshni" sort="Sundaram, Roshni" uniqKey="Sundaram R" first="Roshni" last="Sundaram">Roshni Sundaram</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Department of Microbiology, The Ohio State University, Columbus</wicri:cityArea></affiliation></author><author><name sortKey="Dakappagari, Naveen K" sort="Dakappagari, Naveen K" uniqKey="Dakappagari N" first="Naveen K." last="Dakappagari">Naveen K. Dakappagari</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Departments of Obstetrics and Gynecology, The Ohio State University, Columbus</wicri:cityArea></affiliation></author><author><name sortKey="Kaumaya, Pravin T P" sort="Kaumaya, Pravin T P" uniqKey="Kaumaya P" first="Pravin T. P." last="Kaumaya">Pravin T. P. Kaumaya</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Department of Microbiology, The Ohio State University, Columbus</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Departments of Obstetrics and Gynecology, The Ohio State University, Columbus</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Correspondence address: Suite 316, Tzagournis Medical Research Facility, 420 W. 12th Ave., Columbus</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Peptide Science</title><title level="j" type="alt">PEPTIDE SCIENCE</title><idno type="ISSN">0006-3525</idno><idno type="eISSN">1097-0282</idno><imprint><biblScope unit="vol">66</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="200">200</biblScope><biblScope unit="page" to="216">216</biblScope><biblScope unit="page-count">17</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002">2002</date></imprint><idno type="ISSN">0006-3525</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-3525</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Active immunotherapy</term><term>Adenocarcinoma</term><term>Adjuvant</term><term>Allele</term><term>Amino acids</term><term>Animal models</term><term>Antibody</term><term>Antibody response</term><term>Antibody responses</term><term>Antigen</term><term>Antigen presentation</term><term>Antigen processing</term><term>Antitumor</term><term>Antitumor immunity</term><term>Biodegradable microspheres</term><term>Biol chem</term><term>Cancer immunol immunother</term><term>Cancer patients</term><term>Cancer vaccines</term><term>Cancerous cells</term><term>Cell epitopes</term><term>Cell surface</term><term>Cellular response</term><term>Cellular transformation</term><term>Chain length</term><term>Clin</term><term>Clin cancer</term><term>Clin oncol</term><term>Clinical trials</term><term>Conformational epitopes</term><term>Costimulatory</term><term>Costimulatory molecules</term><term>Ctls</term><term>Curr opin immunol</term><term>Cytokine</term><term>Cytotoxic</term><term>Cytotoxic responses</term><term>Dakappagari</term><term>Dendritic cells</term><term>Different types</term><term>Disis</term><term>Early stage cancer</term><term>Envelope glycoprotein</term><term>Epitope</term><term>Epitope peptides</term><term>Existent immunity</term><term>Foreign species</term><term>Further studies</term><term>Gmcsf</term><term>Granulocyte monocyte colony</term><term>Helper epitopes</term><term>High frequency</term><term>High titered antibodies</term><term>Humoral</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immune system</term><term>Immunization</term><term>Immunogenic</term><term>Immunol</term><term>Immunotherapeutic strategies</term><term>Immunotherapy</term><term>Kaumaya</term><term>Komen breast cancer foundation</term><term>Lesser extent</term><term>Major histocompatibility</term><term>Mammary tumors</term><term>Melanoma</term><term>Melanoma antigen</term><term>Melanoma antigens</term><term>National cancer institute</term><term>National institutes</term><term>Native protein</term><term>Natl</term><term>Nitric oxide</term><term>Objective tumor regressions</term><term>Ohio state university</term><term>Oncogenic virus</term><term>Ovarian cancer patients</term><term>Peptide</term><term>Peptide epitope</term><term>Peptide vaccine</term><term>Peptide vaccines</term><term>Peripheral blood</term><term>Precise mechanism</term><term>Primary sequence</term><term>Prime ctls</term><term>Proc</term><term>Proc natl acad</term><term>Professional antigen</term><term>Promiscuous</term><term>Promiscuous epitopes</term><term>Radiation therapy</term><term>Rational design</term><term>Recent years</term><term>Receptor</term><term>Schematic representation</term><term>Second signal</term><term>Semin immunol</term><term>Side effects</term><term>Subsequent tumor challenge</term><term>Such study</term><term>Sundaram</term><term>Synthetic peptide vaccines</term><term>Synthetic peptides</term><term>Transgenic</term><term>Transgenic mice</term><term>Transgenic mouse model</term><term>Tumor</term><term>Tumor antigen</term><term>Tumor antigens</term><term>Tumor cells</term><term>Tumor development</term><term>Tumor growth</term><term>Tumor immunity</term><term>Tumor site</term><term>Tumor vaccines</term><term>Vaccination</term><term>Vaccination strategies</term><term>Vaccine</term><term>Vaccine strategies</term><term>Viral</term><term>Wiley periodicals</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Effective cancer therapy or prevention has been the dream of physicians and scientists for many years. Although we are still very far from our ultimate goal of cancer prevention, significant milestones have been realized in terms of our knowledge base and understanding of the pathogenesis of cancerous cells and the involvement of the immune system against both self‐ and virus‐associated tumor antigens. Immunotherapeutic strategies are now accepted to being superior in terms of the exquisite specificity that they offer in targeting only tumor cells as opposed to the existent chemotherapy or radiation therapy that is more general and invasive with many associated side effects. There are several immunotherapeutic strategies that are currently under investigation. This review primarily focuses on the significant advances made in the use of synthetic peptides in the development of subunit cancer vaccines. We have attempted to highlight some of the fundamental issues regarding antigen processing and presentation, Major Histocompatibility Complex (MHC) restriction, T‐cell help, structural determinants in antibody recognition, and the use of these concepts in the rational design and delivery of peptide vaccines to elicit protective humoral and cell mediated immune responses. The recent use of costimulatory molecules and cytokines to augment immune responses also has been discussed along with the contributions of our laboratory to the field of synthetic peptide vaccine development. © 2002 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 66: 200–216, 2002</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><country name="États-Unis"><region name="Ohio"><name sortKey="Sundaram, Roshni" sort="Sundaram, Roshni" uniqKey="Sundaram R" first="Roshni" last="Sundaram">Roshni Sundaram</name></region><name sortKey="Dakappagari, Naveen K" sort="Dakappagari, Naveen K" uniqKey="Dakappagari N" first="Naveen K." last="Dakappagari">Naveen K. Dakappagari</name><name sortKey="Kaumaya, Pravin T P" sort="Kaumaya, Pravin T P" uniqKey="Kaumaya P" first="Pravin T. P." last="Kaumaya">Pravin T. P. Kaumaya</name><name sortKey="Kaumaya, Pravin T P" sort="Kaumaya, Pravin T P" uniqKey="Kaumaya P" first="Pravin T. P." last="Kaumaya">Pravin T. P. Kaumaya</name><name sortKey="Kaumaya, Pravin T P" sort="Kaumaya, Pravin T P" uniqKey="Kaumaya P" first="Pravin T. P." last="Kaumaya">Pravin T. P. Kaumaya</name><name sortKey="Kaumaya, Pravin T P" sort="Kaumaya, Pravin T P" uniqKey="Kaumaya P" first="Pravin T. P." last="Kaumaya">Pravin T. P. Kaumaya</name><name sortKey="Kaumaya, Pravin T P" sort="Kaumaya, Pravin T P" uniqKey="Kaumaya P" first="Pravin T. P." last="Kaumaya">Pravin T. P. Kaumaya</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003379 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003379 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1461C1780AD6A3BD609EEA614C751214DB5382AF
|texte= Synthetic peptides as cancer vaccines
}}
| This area was generated with Dilib version V0.6.33. |  |